RPG Life Sciences Sells API Business as Slump Sale to Subsidiary; Details Acquisition of Actis Generics Private Limited

RPG Life Sciences Sells API Business as Slump Sale to Subsidiary; Details Acquisition of Actis Generics Private Limited​

RPG Life Sciences Limited has undertaken significant strategic movements by transferring its Active Pharmaceutical Ingredients (API) business to a wholly owned subsidiary and subsequently acquiring a key intermediate supplier. The moves were approved at the company's Board meeting on July 29, 2026.

The API business of RPG Life Sciences was transferred via a Business Transfer Agreement for Sale of Assets to RPG Active Pharma Limited (RPGAP), a Wholly Owned Subsidiary (WOS). This transaction represents a slump sale and is intended to provide sharp focus on the growth of the API business within the subsidiary while offering operational and strategic flexibility to the parent company.

The key details regarding the API transfer are summarized below:


The sale involved the transfer of the entire API business to RPG Active Pharma Limited. The seller, RPG Life Sciences Limited, has been engaged in manufacturing and marketing Pharmaceutical products and Active Pharmaceutical Ingredients (API) since its incorporation on March 29, 2007. For FY26, the standalone revenue from operations of the company was Rs. 707.52 Crores.

Investment and Acquisition of Actis Generics Private Limited​

In parallel developments aimed at strengthening its API portfolio, RPG Active Pharma Limited entered into an Investment and Shareholders' Agreement (IA) with India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF). This agreement involves the initial aggregate investment of Rs. 243.33 crores in RPGAP by ILSF and VJF. The parties also committed to infusing up to an aggregate amount of Rs. 700 crores, with the aim of utilizing these proceeds for organic and inorganic growth opportunities within the API business.

Furthermore, RPG Active Pharma Limited proceeded with the Share Purchase Agreement for the acquisition of Actis Generics Private Limited (Actis). This strategic move is aligned with the company's strategy to expand its API business. The acquisition is scheduled to be completed on or before November 15, 2026.

The financial and operational details of the acquired entity are as follows:


Actis Generics Private Limited, incorporated on May 3, 2012, specializes as a key Indian supplier of Bulk Drug Intermediates for APIs such as Rivaroxaban, Sitagliptin, and Apixaban. The company has been operating in this space since starting in Visakhapatnam in 2014.

Actis Generics Private Limited’s turnover over the last three audited financial years shows a trend of growth followed by a reduction:

RPGLIFE Stock Price Movement​

On Wednesday, shares of RPG Life Sciences Limited slipped by 1.62% to settle at ₹2850.2, shedding value in the market session. The stock saw 53,983 trades as it traded within a wide range defined by daily lows starting near ₹2768.9 and high levels reaching ₹3019.7.